Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with HER2-positive breast cancer (confirmed by a tissue sample/biopsy) and are planned to receive chemotherapy combined with HER2-blocking treatment, either before or after surgery.
- People aged 18 or older.
- People who are generally well enough to carry out normal daily activities with little or no limitation (this is measured using a standard medical scale called ECOG/WHO 0–1 — confirm with trial site if unsure).
- People whose heart, liver, kidneys, and other organs are functioning well enough to safely receive the planned treatment, according to local medical guidelines.
- People whose cancer has not spread to distant parts of the body.
- People who have a negative pregnancy test taken within 14 days before starting treatment.
- People who are able to become pregnant and are willing to use an effective form of contraception during the trial.
- People who have not had another cancer in the past 5 years, except for certain fully treated skin cancers (basal or squamous cell carcinoma) or cervical carcinoma in situ.
- People who are willing to sign a consent form and follow the trial procedures.
Who may not be able to join:
- People with a history of heart disease that would require special monitoring and carries a high risk of having to stop treatment early.
- People with other significant medical conditions — such as mental health conditions, infections, neurological conditions, or abnormal test results — that could interfere with treatment or affect their ability to follow the trial plan.
- People who are currently pregnant or breastfeeding.
- People who have another active cancer that currently requires treatment (not including non-invasive or very early-stage cancers in situ).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Daniel Giglio, Assoc Prof, Sahlgrenska University Hospital/University of Gothenburg
Phone: +46(0)31-342 16 06
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Sensitivity and specificity of NT-proBNP to detect trastuzumab-induced cardiotoxicity
Can't join this trial?
Data last synced from ClinicalTrials.gov: 21 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.